Mizuho Downgrades Intra-Cellular Therapies (NASDAQ:ITCI) to Neutral
Intra-Cellular Therapies (NASDAQ:ITCI – Get Free Report) was downgraded by research analysts at Mizuho from an “outperform” rating to a “neutral” rating in a research note issued to investors on Monday, Marketbeat reports. They currently have a $132.00 price objective on the biopharmaceutical company’s stock, down from their prior price objective of $140.00. Mizuho’s price […]
Intra-Cellular Therapies (NASDAQ:ITCI – Get Free Report) was downgraded by research analysts at Mizuho from an “outperform” rating to a “neutral” rating in a research note issued to investors on Monday, Marketbeat reports. They currently have a $132.00 price objective on the biopharmaceutical company’s stock, down from their prior price objective of $140.00. Mizuho’s price […]
